In the CCLG-ALL-2008 cohort, mortality was significantly lower in patients with high CD123 expression (9.1%, 16/175) as compared to those with lower CD123 expression (23.9%, 17/71) or negative CD123 expression (19.5%, 16/82; p = 0.005). This evidence concerns the gene IL3RA and acute lymphoblastic leukemia.